Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Phase 2 Completed 244 enrolled Vir Biotechnology, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy

Timeline

Start: 2021-07-11
Primary completion: 2026-03-16
Completion: 2026-03-16

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “We are pleased to share encouraging data from the MARCH trial, which suggest that VIR-2218 and VIR-3434 are additive in reducing hepatitis B surface antigen” vir.bio ↗

release “Part A of the MARCH trial demonstrated that the combination of VIR-3434 and VIR-2218 resulted in an approximate 3 log decline” vir.bio ↗

Publications

Noack J, Anglero-Rodriguez Y, Gall J, Zhou J, LeBlanc S, Liebow A, Bakardjiev A, Hebner CM, Purcell LA, Jadhav V, Corti D, Lempp FA. Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical in vivo models. Antimicrob Agents Chemother. 2026 Mar 4;70(3):e0112725. doi: 10.1128/aac.01127-25. Epub 2026 Jan 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PEG-IFNα	Protein / enzyme biologic	—	Subcutaneous
Subject	Tobevibart	Monoclonal antibody	—	Subcutaneous
Subject	VIR-2218	Small interfering RNA (siRNA)	—	Subcutaneous